Former Merck and NASA Leaders Bring Strategic Expertise to SpaceMD Amid Rising Demand for its In-Space Pharmaceutical Development Capabilities

Key Terms

microgravity technical

Microgravity is a condition where objects experience almost no net weight because they are in continuous free-fall, such as aboard orbiting spacecraft; think of passengers feeling weightless in a smoothly falling elevator. For investors, microgravity matters because it enables scientific experiments and manufacturing processes that behave very differently than on Earth, potentially creating novel drugs, materials, or technologies, changing development timelines, costs, market opportunities and regulatory considerations.

immunotherapy medical

Treatment that uses or enhances the body’s immune system to detect and fight disease, most often cancers or chronic infections; think of it as training or arming the body’s own soldiers to find and destroy targets. It matters to investors because successful immunotherapies can lead to high-value drug approvals, recurring revenue from long-term treatments, and changes in competitive dynamics, while failures or safety issues in clinical trials can materially affect company valuations.

international space station (iss) technical

A large orbiting laboratory and living module jointly operated by multiple nations where scientists and companies run experiments, test space technologies, and host commercial services; think of it as a floating research campus and service hub circling Earth. It matters to investors because it creates markets for satellite launches, manufacturing in microgravity, supply and crew transport, and related contracts and technologies, while its operating life and funding influence revenue opportunities and risk for those businesses.

orbital research and manufacturing pipeline technical

A sequence of projects, facilities and activities that move scientific experiments and manufacturing processes through development, testing and production in orbit around Earth. It covers everything from designing experiments for microgravity, launching hardware to a space station or orbital factory, running tests or production runs in microgravity, and returning results or finished goods to Earth. For investors, it is like a product development pipeline on Earth but stretched into space, showing potential technical milestones, timelines, capital needs and commercial applications.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

JACKSONVILLE, Fla.--(BUSINESS WIRE)-- Redwire Corporation (NYSE: RDW), a global leader in aerospace and defense technology solutions, announced today it has appointed pioneering industry leaders Paul Reichert, former Principal Investigator at Merck Research Laboratories, and Niki Werkheiser, former Director of Technology Maturation at NASA’s Space Technology Mission Directorate, to serve in strategic advisory roles at Space Microgravity Development LLC (SpaceMD), Redwire’s venture company focused on leveraging the microgravity environment to create new innovations in biotech and other fields. Specifically, Reichert and Werkheiser will expand SpaceMD’s leadership in space-enabled research and pharmaceutical innovation as it accelerates work with a growing number of pharmaceutical customers and partners.

As Scientific Advisor, Reichert will shape SpaceMD’s scientific and commercial roadmap by identifying promising drug candidates and supporting the development of an orbital research and manufacturing pipeline. In her role as SpaceMD’s Strategic Advisor, Werkheiser will work closely with the SpaceMD team and biotech partners to develop new therapeutic concepts and establish new opportunities to apply SpaceMD technologies to pharmaceutical research on the International Space Station (ISS) and emerging commercial platforms.

“SpaceMD’s mission is to unlock new pharmaceutical drugs through cutting-edge, space-based research. Bringing Paul and Niki onto our advisory team significantly advances that mission,” said John Vellinger, CEO of SpaceMD. “Their unparallelled expertise in drug development and go-to-market strategy, biopharmaceutical research, and space technology will bolster the momentum already underway as SpaceMD continues to lead the industry in in‑space pharmaceutical research.”

While at Merck, Reichert played a key role in advancing the company’s research pipeline. Notably, he contributed to the early formulation and crystallization research of pembrolizumab—the active ingredient in Keytruda, a breakthrough immunotherapy used to treat multiple cancers. Reichert’s work at Merck and Schering-Plough has helped shape the pharmaceutical industry's understanding of molecular behavior, formulation challenges, and drug development pathways.

Werkheiser advises across the commercial space ecosystem - drawing from three decades of experience successfully leading space programs and partnerships from concept to operations on space shuttles, the International Space Station (ISS), and the lunar surface. Most recently, she served as NASA's director of technology maturation, where she oversaw more than $1.5B in technology investments across industry and government. Previously, she established NASA’s In-Space Manufacturing Initiative as a foundational capability for long-duration missions.

SpaceMD leverages the unique microgravity environment in space using its innovative and flight-proven Pharmaceutical In-Space Laboratory (PIL-BOX) technology to grow seed crystals in space, for subsequent sale or licensing to companies that can use them to reformulate existing drugs or develop entirely new therapeutics. Since the first PIL-BOX launch in November 2023, 54 PIL-BOX systems have flown to the ISS, successfully crystallizing 45 unique compounds, including insulin and other critical molecules for treating diseases like cancer, cardiovascular disease, obesity, and diabetes.

About SpaceMD

SpaceMD is a subsidiary of Redwire Corporation focused on leveraging the microgravity environment of space to create new advances in pharmaceuticals, biotechnology, and other fields. SpaceMD utilizes innovative, flight-proven Redwire hardware to conduct this potentially life-enhancing work. SpaceMD uses the unique nature of space to benefit life on Earth.

About Redwire

Redwire Corporation (NYSE:RDW) is an integrated space and defense tech company focused on advanced technologies. We are building the future of aerospace infrastructure, autonomous systems, and multi-domain operations leveraging digital engineering and AI automation. Redwire’s approximately 1,400 employees located throughout North America and Europe are committed to delivering innovative space and airborne platforms transforming the future of multi-domain operations. For more information, please visit RDW.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260708178055/en/

Media Contact:
Tere Riley
Tere.Riley@rdw.com

OR

Investors:
Investorrelations@rdw.com

Source: Redwire Corporation